Assessing adherence to oral chemotherapy using different measurement methods: Lessons learned from capecitabine

Abstract

Purpose

Adherence to oral medication is important in oncology. Few studies have evaluated adherence with cancer agents such as capecitabine, which is given on a complicated schedule. Furthermore, little guidance exists regarding the best methods for monitoring adherence with oral cancer drugs. The purpose of our study was to evaluate adherence to capecitabine using several accepted measures.

Patients and methods

Patients treated with capecitabine for gastrointestinal cancers were included in this prospective cohort study. Adherence was evaluated during two consecutive cycles of capecitabine using three assessment methods: self-report, pill count, and use of a microelectronic monitoring system. The primary endpoint was proportion of patients adherent to capecitabine (>80% of adherence according to the three methods of measurement); the secondary objective was to compare the three methods of measurement.

Results

Nineteen patients were accrued to this study. Further accrual was stopped after the first planned analysis, because 18 and 19 patients were adherent by self-report and pill count, respectively. The overall adherence rates were 99, 100, and 61% with self-report, pill count, and microelectronic monitoring system cap, respectively. Ten (53%) patients were classified as nonadherent (<80% of adherence according to at least one method of measurement), but four of them transferred their pills into another medication container suggesting that measurement of adherence using microelectronic monitoring system technology may not be useful.

Conclusion

While we did not identify a major adherence issue with capecitabine in our study, it provides insight into problems associated with measurement of adherence in oncology and suggests that combining measures of adherence maximizes accuracy.

Keywords

Adherence capecitabine microelectronic monitoring oral anticancer agents

Get full access to this article

View all access options for this article.

References

Dematteo

Ballman

Antonescu

. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial. Lancet 2009; 373: 1097–1104.

Joensuu

Eriksson

Sundby Hall

. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA 2012; 307: 1265–1272.

Liu

Franssen

Fitch

. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110–115.

Marin

Bazeos

Mahon

. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol 2010; 28: 2381–2388.

Ibrahim

Eliasson

Apperley

. Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy. Blood 2011; 117: 3733–3736.

Ruddy

Mayer

Partridge

. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin 2009; 59: 56–66.

Osterberg

Blaschke

. Adherence to medication. N Engl J Med 2005; 353: 487–497.

Waterhouse

Calzone

Mele

. Adherence to oral tamoxifen: A comparison of patient self-report, pill counts, and microelectronic monitoring. J Clin Oncol 1993; 11: 1189–1197.

Partridge

Archer

Kornblith

. Adherence and persistence with oral adjuvant chemotherapy in older women with early-stage breast cancer in CALGB 49907: Adherence companion study 60104. J Clin Oncol 2010; 28: 2418–2422.

10.

Love

. Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 1990; 82: 18–21.

11.

Fisher

Costantino

Redmond

. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989; 320: 479–484.

12.

Partridge

Avorn

Wang

. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002; 94: 652–661.

13.

Cramer

Mattson

Prevey

. How often is medication taken as prescribed? A novel assessment technique. JAMA 1989; 261: 3273–3277.

14.

Winterhalder

Hoesli

Delmore

. Self-reported compliance with capecitabine: Findings from a prospective cohort analysis. Oncology 2011; 80: 29–33.

15.

Bhattacharya

Easthall

Willoughby

. Capecitabine non-adherence: Exploration of magnitude, nature and contributing factors. J Oncol Pharm Pract 2012; 18: 333–342.

16.

Timmers

Swart

Boons

. The use of capecitabine in daily practice: A study on adherence and patients’ experiences. Patient Prefer Adherence 2012; 6: 741–748.

17.

Leventhal

Nerenz

Leventhal

. The behavioral dynamics of clinical trials. Prev Med 1991; 20: 132–146.

18.

Ruddy

Pitcher

Archer

. Persistence, adherence, and toxicity with oral CMF in older women with early-stage breast cancer (Adherence Companion Study 60104 for CALGB 49907). Ann Oncol 2012; 23: 3075–3081.

19.

Thivat

Van Praagh

Belliere

. Adherence with oral oncologic treatment in cancer patients: Interest of an adherence score of all dosing errors. Oncology 2013; 84: 67–74.

20.

Lee

Nicholson

Souhami

. Patient compliance with oral chemotherapy as assessed by a novel electronic technique. J Clin Oncol 1992; 10: 1007–1013.

21.

Macintosh

Pond

. A comparison of patient adherence and preference of packaging method for oral anticancer agents using conventional pill bottles versus daily pill boxes. Eur J Cancer Care (Engl) 2007; 16: 380–386.

22.

Lee

Nicholson

Souhami

. Patient compliance with prolonged low-dose oral etoposide for small cell lung cancer. Br J Cancer 1993; 67: 630–634.

23.

Lebovits

Strain

Schleifer

. Patient noncompliance with self-administered chemotherapy. Cancer 1990; 65: 17–22.

24.

Levine

Richardson

Marks

. Compliance with oral drug therapy in patients with hematologic malignancy. J Clin Oncol 1987; 5: 1469–1476.